Literature DB >> 12197834

Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

Chun-Nam Lok1, Alexander J Lang, Shelagh E L Mirski, Susan P C Cole.   

Abstract

Eukaryotic topoisomerase II (topo II) catalyses topological genomic changes essential for chromosome segregation, chromatin reorganization, DNA replication and transcription. Mammalian topo II exists as two isoforms, designated alpha and beta. Human topo IIalpha is an important cancer drug target, and an established determinant of drug sensitivity and resistance. Human topo IIbeta is also the target of anticancer drugs but its role in drug resistance is less clear. The two human topo II proteins are encoded by the TOP2A and TOP2B genes, respectively, which despite their highly conserved structural organization, are subject to distinctly different modes of regulation. In the present study, we have cloned and characterized the human TOP2B promoter containing a 1.3 kb fragment of the 5'-flanking and untranslated region (-1067 to +193). We found that the promoter activity of this TOP2B fragment was constant throughout the cell cycle, in contrast to the activity of the proximal promoter of TOP2A which was low in resting cells and enhanced during proliferation. Analyses of 5'-serially and internally deleted luciferase reporter constructs revealed that 80% of the TOP2B promoter activity could be attributed to the region between -533 and -481. Mutational analyses of putative regulatory elements indicated that two inverted CCAAT boxes (ICBs) within this region were essential for TOP2B promoter activity and gel mobility-shift assays indicated these sites bound the transcription factor nuclear factor-Y (NF-Y). Co-transfection experiments using a dominant-negative form of subunit A of NF-Y suggested that TOP2B promoter activity required direct interaction of NF-Y with the ICBs. In addition, a specificity protein-1 (Sp1)-binding GC box located just upstream of the ICBs was shown to contribute to TOP2B promoter activity in a synergistic manner with the ICBs. Our results suggest that the binding sites for NF-Y and Sp1 are critical for TOP2B transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197834      PMCID: PMC1223026          DOI: 10.1042/BJ20020791

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  51 in total

Review 1.  Tumor cell death induced by topoisomerase-targeting drugs.

Authors:  T K Li; L F Liu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 2.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

3.  Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.

Authors:  S E Morgan; W T Beck
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

4.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Authors:  F H Drake; G A Hofmann; H F Bartus; M R Mattern; S T Crooke; C K Mirabelli
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

5.  The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.

Authors:  E U Kurz; S E Wilson; K B Leader; B P Sampey; W P Allan; J C Yalowich; D J Kroll
Journal:  Mol Cancer Ther       Date:  2001-12       Impact factor: 6.261

6.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.

Authors:  M Tsai-Pflugfelder; L F Liu; A A Liu; K M Tewey; J Whang-Peng; T Knutsen; K Huebner; C M Croce; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity.

Authors:  Didier Jean; Nathalie Guillaume; Raymond Frade
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

8.  CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure.

Authors:  F Coustry; Q Hu; B de Crombrugghe; S N Maity
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

9.  A multiplicity of CCAAT box-binding proteins.

Authors:  A Dorn; J Bollekens; A Staub; C Benoist; D Mathis
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

10.  NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest.

Authors:  I Manni; G Mazzaro; A Gurtner; R Mantovani; U Haugwitz; K Krause; K Engeland; A Sacchi; S Soddu; G Piaggio
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

View more
  7 in total

1.  Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.

Authors:  Chandra M Das; Peter E Zage; Pete Taylor; Dolly Aguilera; Johannes E A Wolff; Dean Lee; Vidya Gopalakrishnan
Journal:  Eur J Cancer       Date:  2010-10       Impact factor: 9.162

2.  Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells.

Authors:  Gisela Kersting; Mladen V Tzvetkov; Klaus Huse; Bettina Kulle; Verena Hafner; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-07       Impact factor: 3.000

3.  Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell.

Authors:  Najing Zhou; Yunli Yan; Wenling Li; Yanling Wang; Lifen Zheng; Shuo Han; Yongxin Yan; Yunzhi Li
Journal:  Int J Mol Sci       Date:  2009-07-22       Impact factor: 6.208

4.  HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.

Authors:  Michal Stros; Eva Polanská; Sona Struncová; Sárka Pospísilová
Journal:  Nucleic Acids Res       Date:  2009-02-17       Impact factor: 16.971

5.  Long-range enhancer associated with chromatin looping allows AP-1 regulation of the peptidylarginine deiminase 3 gene in differentiated keratinocyte.

Authors:  Stéphane Chavanas; Véronique Adoue; Marie-Claire Méchin; Shibo Ying; Sijun Dong; Hélène Duplan; Marie Charveron; Hidenari Takahara; Guy Serre; Michel Simon
Journal:  PLoS One       Date:  2008-10-16       Impact factor: 3.240

6.  NF-Y Binding Site Architecture Defines a C-Fos Targeted Promoter Class.

Authors:  Martin Haubrock; Fabian Hartmann; Edgar Wingender
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

Review 7.  TOP2B: The First Thirty Years.

Authors:  Caroline A Austin; Ka C Lee; Rebecca L Swan; Mushtaq M Khazeem; Catriona M Manville; Peter Cridland; Achim Treumann; Andrew Porter; Nick J Morris; Ian G Cowell
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.